Samantha Williams
Primary Care · Birmingham, ALNPI 1588158877
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations.
Across 237 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$862
- Lilly USA, LLC$822
- Dexcom, Inc.$410
- Pfizer$392
- GSK$363
- Amgen$232
- plus $1K from 17 others
Across 9 payments — averaging $1973.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$7K
- Modernatx, Inc.$6K
- Sanofi Pasteur Inc.$4K
What the payments were for
- Food & beverage$4,267100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $862 |
| Lilly USA, LLC | 46 | $822 |
| Dexcom, Inc. | 26 | $410 |
| Pfizer | 23 | $392 |
| GSK | 19 | $363 |
| Amgen | 11 | $232 |
| Boehringer Ingelheim | 10 | $162 |
| Bard Peripheral Vascular, Inc. | 1 | $154 |
| AstraZeneca | 8 | $148 |
| Astellas Pharma US Inc | 7 | $148 |
| Exact Sciences | 6 | $106 |
| Bayer | 6 | $101 |
| Teleflex LLC | 4 | $85 |
| Abbott | 4 | $80 |
| Corcept Therapeutics | 3 | $54 |
| Inari Medical, Inc. | 1 | $26 |
| Mylan Specialty L.p. | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Vertex | 1 | $15 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,267 in reported general payments places this provider in the 85th percentile of 159 primary care providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 80 | $116,828 |
| OzempicSemaglutide | 74 | $97,710 |
| JardianceEmpagliflozin | 50 | $70,152 |
| TrulicityDulaglutide | 48 | $70,053 |
| EliquisApixaban | 62 | $53,403 |
| JanuviaSitagliptin Phosphate | 25 | $25,114 |
| MyrbetriqMirabegron | 21 | $24,308 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,319 |
| XareltoRivaroxaban | 14 | $11,255 |
| Atorvastatin Calcium | 252 | $2,855 |
| Duloxetine Hcl | 80 | $2,481 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,276 |
| Amlodipine Besylate | 223 | $1,792 |
| Potassium Chloride | 57 | $1,719 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 61 | $1,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $822 | $186,881128 claims |
| Novo NordiskOzempic | $862 | $97,71074 claims |
| Boehringer IngelheimJardiance | $162 | $70,15250 claims |
| PfizerEliquis | $392 | $53,40362 claims |
| MerckJanuvia | $14 | $25,11425 claims |
| Astellas Pharma US IncMyrbetriq | $148 | $24,30821 claims |
| GSKTrelegy Ellipta | $363 | $15,31922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 159 primary care providers in Alabama.
Other primary care in Birmingham
- Josh WarrenBirmingham$9K
- Jill AroraBirmingham$6K
- Bevin EllenbergBirmingham$5K
- Barbara BoreenBirmingham$4K
- Joanna ReavesBirmingham$3K
- Anna MesserBirmingham$2K
- Hannah WuisanBirmingham$2K
- Tiffany LasernaBirmingham$2K
- Holly StraussBirmingham$2K
- Brooke LittleBirmingham$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.